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Objectives: Previous Australian research has shown that following
the 21% increase in patient copayments for medications on the
Pharmaceutical Benefits Scheme (PBS) in 2005, the use of lipidlowering therapy declined by 5%. This study aimed to determine
the demographic and clinical characteristics of individuals who
continued, reduced or ceased their use of statin medication in 2005.

Key points
• The proportion of individuals who reduced or ceased
use of statin medications in 2005 increased by 2.1%
compared with 2004, following an increase in the
Pharmaceutical Benefits Scheme copayment for
medications
• Of those who ceased or reduced statin use, 8% and
10%, respectively, had prior heart disease, putting
them at an increased risk of harms from suboptimal
use of lipid-lowering therapy
• General beneficiary status, and younger and healthier
people were particularly at risk of ceasing or reducing
statin medication
• The findings provide policy makers and clinicians
with new information about the impact of a large
increase in the medication copayment on the use of
medications by specific subgroups

Study type: Retrospective observational study using routinely
collected administrative data.
Method: We used pharmaceutical claims, hospital separations
and mortality records from 2000 to 2005 for the Western Australian
population. The cohort comprised stable users of statin medication
in 2004. Based on changes in statin use between 2004 and 2005, we
identified individuals who: 1) continued using statins; 2) reduced their
use by ≥20%; or 3) ceased therapy for at least the first 6 months in
2005. Multivariate logistic regression models were used to determine
whether the demographic and clinical characteristics of the three
groups differed.
Results: There were 205 924 statin users identified in Western
Australia as of December 2004. After the January 2005
Pharmaceutical Benefits Scheme (PBS) copayment increase, 3.2% of
users ceased their regular statin therapy, 12.9% reduced statin use
and 83.9% continued statin use. This represented a 2.1% increase
in statin users reducing or ceasing therapy compared to 2004.
Predictors of cessation and reduction of statin therapy included
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younger age, greater socio-economic disadvantage, residing in very
remote areas, having general beneficiary status, being a new statin
user, having no prior history of ischaemic heart disease, having no
prior history of a coronary artery revascularisation procedure, taking
no other cardiovascular medication or diabetic medication, taking
an increased number of medications, and having a lower level of
adherence to statin medication in 2004.
Conclusion: Compared to 2004, an additional 2.1% of statin users
reduced or discontinued medication use in 2005, which may be
attributed to an increase in the medication copayment. Individuals
with general beneficiary status, and younger and healthier people
were at particular risk of cessation or reduction in statin use in 2005.

Introduction

Previous studies investigating the impact of the 2005
PBS copayment increase have been restricted to using
aggregate data with limited information on individual patient
characteristics, or small self-reported samples. The effects
of the 2005 copayment increase need to be explored
further using individual-level data. To date, the Austalian
Government has not introduced another copayment
increase of this magnitude. We aimed to determine the
demographic and clinical characteristics of individuals
who ceased or reduced statin medication use after the
January 2005 PBS copayment increase in Australia,
compared with individuals who continued statin use.

Feasible solutions are needed to contain rising healthcare
costs, including those of medications, in private and
public healthcare services.1 Many subsidised medication
programs, such as the Pharmaceutical Benefits Scheme
(PBS) in Australia, have adopted a consumer copayment
scheme to offset health costs. Consumer copayments
were introduced by the Australian Government via the
PBS in 1960, and are one of many policies adopted
to manage rising healthcare costs. Under the PBS,
consumers pay an out-of-pocket cost (copayment)
for their medications. The copayment depends on the
consumer’s beneficiary status (general or concessional),
which is largely based on the individual’s ability to pay.2
PBS copayments increase annually, generally in
line with inflation.2 However, on 1 January 2005, a 21%
copayment increase occurred for both general patients
(from AU$23.70 to AU$28.60 per item dispensed) and
concessional patients (AU$3.80 to AU$4.60).
Large increases in the PBS copayment are of concern
from an individual and population health perspective.
National and international evidence suggests that rising
medication costs can result in consumers ceasing or
reducing their medication use.3-5
Previous research using aggregated data has
demonstrated that, following the PBS copayment increase
in January 2005, the volume of medication dispensed in
Australia decreased significantly (from 3% to 11% for 12
of the 17 medication categories examined).3 The largest
reductions were observed for concessional (lower-income)
individuals. Essential medications used to manage serious
but asymptomatic conditions, such as lipid-lowering
therapy, were among the most affected at a population
level, with dispensing decreasing by 5%.6 Although a 5%
change is small in relative terms, it is large in absolute
terms in this particular instance and has serious potential
for harm. An Australian study demonstrated that statin
dispensing in Australia fell by 2.6% following a 2013
television program that was critical of statin therapy, and
estimated that this resulted in between 1522 and 2900
preventable heart attacks and strokes.7

Methods
Study design
This retrospective observational study used wholeof-population linked pharmaceutical claims, hospital
inpatient and mortality register records for 2000–2005 in
Western Australia (WA).
Approval was obtained from the Human Research
Ethics Committees of the WA Department of Health
(2012/26), the University of Western Australia
(RA/4/1/1775) and the University of Notre Dame
(014167F).

Study cohort
The cohort was defined as all individuals residing in WA
who were stable statin users as of December 2004. A
stable statin user was defined as an individual who had
at least 60 days supply of statin medication in the last
3 months or 150 days supply in the last 6 months of 2004.
Individuals were excluded if they were aged <18 years
in 2004, died before January 2006 or had a medication
possession ratio (MPR) in 2004 of >150%. The 150%
cut-off was chosen because Australian regulations allow
up to 6 months supply of a medication at once in special
circumstances, and to account for standard end-of-year
fluctuations in dispensing frequency due to the PBS
Safety Net.8,9
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Statins were identified in the PBS dataset using the
Anatomical Therapeutic Chemical (ATC) codes C10AA01,
C10AA03, C10AA04, C10AA05, C10AA06 and C10AA07.

user’. Prior use of cardiovascular or diabetes medication
was defined as a dispensing during 2004 of any therapy
with ATC codes C01–C10 (except C10AA) or A10,
respectively.14,15 The number of other medications was
based on the number of unique PBS codes dispensed in
2004.
Hospital separations for 2000–2004 were used to
determine whether individuals were using statins for
primary or secondary prevention of ischaemic heart
disease (IHD) or stroke, and whether they had had a prior
coronary artery revascularisation procedure (CARP). This
information was identified from all diagnosis fields for
IHD and stroke, and all producer fields for CARP in the
HMDC data, using the ICD-10-AM (International Statistical
Classification of Diseases and Related Health Problems,
10th revision, with Australian modifications) codes I20–I25
for IHD, and I60–I61, I63 and I64 for stroke.16,17

Data sources and linkages
This study used de-identified linked data provided by the
Australian Government Department of Human Services
and the WA Department of Health. Linkage of three
independent datasets occurred at the individual patient
level through the WA Data Linkage System, as described
elsewhere.10 The three datasets were: 1) pharmaceutical
claims comprising all PBS-subsidised medications from
May 2002 to December 2005; 2) WA Mortality Register
data for 2000–2005 that included all deaths in WA; and 3)
WA Hospital Morbidity Data Collection (HMDC) records
for 2000–2004 that included all discharges from WA
public and private hospitals.

Statistical analysis

Comparison groups

Descriptive statistics were used to compare the type of
statin user, dichotomised (yes/no) as a user who has
continued, reduced or ceased therapy. Crude differences
in characteristics among the three user groups (ceased
versus continued; reduced versus continued) were
initially compared using one-way ANOVA for continuous
variables and chi-squared tests for categorical variables.
Univariate and multivariate logistic regression models
were applied to ceased versus continued (the reference
group) and reduced versus continued (the reference
group). Unadjusted and adjusted odds ratios (OR) and
95% confidence intervals (CI) were calculated for each
characteristic. All analysis was stratified by beneficiary
status. The study was replicated using 2003–2004 data
to determine the proportion of the population that may
have ceased or reduced medicine use as a result of the
copayment. Bonferroni corrections were applied to all
statistical analyses to account for multiple testing. All
analyses were conducted using Stata Statistical Software
(College Station, TX: StataCorp LLC; Release 15).

The primary outcome was the change in the level of statin
use in 2005, categorised as either continued, reduced
or ceased use. Statin adherence levels were calculated
for 2004 and 2005 separately using the MPR, which is
a proxy measure of medication use. The proportion of
days covered could not be calculated as only month of
supply, and not actual supply date, was available in the
PBS dataset. MPR was computed as the portion of days
covered by dispensing from the first day of the month of
the first dispensing in the year until the end of the year.
Individuals who continued statin therapy were defined as
those with a change in MPR from 2004 to 2005 of ≤20%
or an MPR of ≥80% in 2005. Reduction in therapy was
defined as an MPR change of >20%, and individuals were
classified as ceased users if there was no dispensing
in 2005 or no dispensing for the first 6 months of 2005.
The 80% threshold of adherence was based on previous
studies on adherence for statin medication.11

Demographic and clinical characteristics
PBS data from the last dispensing in 2004 were used
to determine baseline age, sex, area-based social
disadvantage, residential remoteness, PBS beneficiary
status including Department of Veterans’ Affairs
healthcare card eligibility, number of other medications
dispensed, and prior use of cardiovascular or diabetes
medication. Area-based social disadvantage was
classified using the Index of Relative Socio-Economic
Disadvantage which is based on postal area.12 This
variable was then divided into quintiles. Level of
residential remoteness (as a proxy for access to
healthcare services) was assessed using the Accessibility
Remoteness Index of Australia and divided into five
categories.13
Individuals were classified as a new statin user if PBS
data showed no dispensing of a statin medication in 2002
or 2003; otherwise they were classified as an ‘existing

Results
Cohort characteristics
There were 205 924 stable statin users in WA as of
December 2004. Of these, 83.9% continued statin
medication in 2005, 12.9% had a reduction in use of
>20%, and 3.2% ceased statin use for at least the
first 6 months of 2005. The three groups had baseline
differences across the examined predictors (Table 1).
Compared with individuals who continued statin use,
those who ceased or reduced their use of statins in 2005
were younger, had less medical history of IHD, stroke and
CARP, and were more likely to have general beneficiary
status.

3

Characteristics
Average age (years ± SD)
Age (years) (%)

Continued therapy
(n = 172 692,
83.9%)

Reduced therapy
(n = 26 538,
12.9%)

66.0 ± 10.9

62.8 ± 12.5

Reduced versus
continued
p value
<0.01

Ceased therapy
(n = 6694, 3.2%)
62.8 ± 12.6

≤40

1.4

3.7

41–50

7.0

12.7

51–60

21.9

27.5

28.2

61–70

33.1

26.9

26.5

71–80

28.4

21.3

20.6

8.2

7.9

8.3

48.0
52.0

47.3
52.7

0.05

48.1
51.9

10.6
18.0
24.9
19.4
25.7
1.4

11.4
17.9
23.8
19.3
26.0
1.6

<0.01

Major cities

66.5

66.9

Inner regional

19.6

18.0

<0.01

Outer regional

11.1

11.7

11.4

Remote

2.2

2.5

Very remote

0.5

Unknown

>80

<0.01

3.9
12.5

Ceased versus
continued
p value

Reduced therapy
adjusted OR
(95% CI)

Ceased therapy
adjusted OR
(95% CI)

<0.01

NA

NA

<0.01

1.99 (1.81, 2.19)

2.00 (1.68, 2.36)

1.47 (1.37, 1.57)

1.48 (1.30, 1.68)

1.13 (1.07, 1.20)

1.22 (1.09, 1.37)

0.85 (0.80, 0.90)

0.94 (0.84, 1.04)

0.82 (0.77, 0.87)

0.85 (0.77, 0.94)

1

1

0.82

1.03 (1.00, 1.06)
1

1.04 (0.99, 1.10)
1

11.4
18.0
22.7
19.9
26.4
1.6

<0.01

1.13 (1.08, 1.19)
1.08 (1.03, 1.12)
1.02 (0.98, 1.06)
1.02 (0.98, 1.06)
1
0.99 (0.89, 1.12)

1.11 (1.01, 1.22)
1.08 (0.99, 1.17)
0.98 (0.91, 1.06)
1.04 (0.97, 1.12)
1
1.02 (0.82, 1.25)

68.1

<0.01

1

1

0.95 (0.91, 0.98)

0.89 (0.83, 0.96)

2.4

1.00 (0.92, 1.09)

1.01 (0.86, 1.19)

0.8

0.9

0.1

0.1

0.1

1.28 (1.09, 1.49)

1.40 (1.07, 1.84)

Yes

11.1

9.9

No

88.9

90.1

Sex (%)
Female
Male

4

Socio-economic disadvantage (%)
Most (1)
2
3
4
Least (5)
Unknown
Remoteness (%)

Previous IHD, 2000–2004 (%)

<0.01

17.1

8.4
91.6

1.00 (0.96, 1.05)

<0.01

0.95 (0.87, 1.03)

1.09 (0.70, 1.71)

0.81 (0.32, 2.06)

1

1

1.01 (0.95, 1.07)

1.17 (1.04, 1.31)
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Table 1. Demographic and clinical characteristics of individuals who continued, reduced or ceased statin medication in 2005 (n = 205 924), and adjusted odds
ratios for reduction or cessation of statin therapy compared with continued therapy

Table 1. continued
Reduced therapy
(n = 26 538,
12.9%)

Reduced versus
continued
p value

Ceased therapy
(n = 6694, 3.2%)

Ceased versus
continued
p value

Yes

1.3

1.2

0.14

1.1

0.26

No

98.7

98.8

Yes

5.1

4.5

No

94.9

95.5

Yes

90.7

79.5

No

9.3

20.5

General

26.1

35.4

Concessional

73.9

64.6

Yes

73.0

63.4

No

27.0

36.6

Yes

16.2

14.6

No

83.8

85.4

Characteristics

Reduced therapy
adjusted OR
(95% CI)

Ceased therapy
adjusted OR
(95% CI)

1

1

1.04 (0.92, 1.17)

1.16 (0.92, 1.47)

1

1

1.08 (0.99, 1.17)

1.39 (1.17, 1.65)

1

1

2.33 (2.25, 2.42)

3.30 (3.11, 3.51)

1.17 (1.12, 1.21)

1.41 (1.32, 1.52)

1

1

1

1

1.32 (1.27, 1.36)

1.29 (1.22, 1.37)

1

1

1.06 (1.02, 1.10)

0.99 (0.92, 1.06)

Previous stroke, 2000–2004 (%)
98.9

Previous CARP, 2000–2004 (%)
<0.01

3.3

<0.01

96.7

Previous statin use, 2002 and 2003 (%)
<0.01

74.4

<0.01

25.6

Beneficiary status (%)

5

<0.01

36.1

<0.01

63.9

Cardiovascular medication, 2004 (%)
<0.01

64.5

<0.01

35.5

Diabetic medication, 2004 (%)
<0.01

16.2

0.97

83.5

Average (±SD) number of other
medications, 2004

9.0 ± 6.5
(Median: 8; IQR:
4–12)

8.4 ± 6.9
(Median: 7; IQR:
3–12)

<0.01

9.3 ± 7.5
(Median: 8; IQR:
3–13)

<0.01

1.02 (1.01, 1.02)

1.04 (1.04, 1.05)

Average (±SD) MPR, 2004

93.8 ± 15.5
(Median: 98.6;
IQR: 88.5–98.8)

91.2 ± 18.0
(Median: 90.4;
IQR: 80.8–98.8)

<0.01

87.9 ± 24.3
(Median: 87.6;
IQR: 73.7–98.9)

<0.01

0.99 (0.99, 0.99)

0.98 (0.98, 0.98)

CARP = coronary artery revascularisation procedure; CI = confidence interval; IHD = ischaemic heart disease; IQR = interquartile range; MPR = medication possession ratio; OR = odds ratio;
PDC = proportion of days covered; SD = standard deviation; NA = not applicable
Note:
Tests were considered significantly different if p < 0.0167 (after Bonferroni adjustment). Bold indicates statistical significance. Models were also adjusted for individuals who held a Department
of Veterans’ Affairs healthcare card as a binary variable.
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Continued therapy
(n = 172 692,
83.9%)
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Characteristics associated with ceasing statin
medication in 2005

having 5% lower odds of reducing, while individuals living
in very remote areas were 28% more likely to reduce
statin use.
Individuals who were new statin users had increased
odds of reducing use compared with those with a history
of statin use (adjusted OR 2.33; 95% CI 2.25, 2.42).
Individuals with general beneficiary status had a 17%
increase in their odds of reducing statin use compared
with those with concessional beneficiary status. For
individuals not taking other cardiovascular medication,
the odds of reducing increased by 32% compared
with those taking cardiovascular medication. Those not
taking diabetes medication in 2004 were more likely to
reduce statin use (adjusted OR 1.06; 95% CI 1.02, 1.10).
A 2% increase in the odds of reducing was observed
for every additional medication dispensed. Higher
adherence levels in 2004 were significantly associated
with individuals being less likely to reduce use of the
medication (adjusted OR 0.99; 95% CI 0.99, 0.99). Sex,
history of IHD, history of stroke and history of CARP were
not significant predictors of reducing statin therapy.
When stratified by beneficiary status, women who
were general beneficiaries had increased odds of
reducing statin use (adjusted OR 1.06; 95% CI 1.01, 1.11)
compared with males, but this was not a significant
predictor for concessional beneficiaries (Supplementary
Table 2A, available from: researchonline.nd.edu.au/med_
article/1022/). For individuals with general beneficiary
status, living in inner regional areas was associated
with 13% lower odds of reducing statin use compared
with those living in major cities, while concessional
beneficiaries living in very remote areas had 56%
increased odds of reducing use compared with those
living in major cities.

The overall univariate results (Supplementary
Table 1A, available from: researchonline.nd.edu.au/
med_article/1022/) were similar to the adjusted analysis
(Table 1). Younger adults had higher odds of cessation
compared with those aged >80 years (≤40 years
adjusted OR 2.00; 95% CI 1.68, 2.36). Individuals living
in inner regional areas were less likely to cease statin
use compared with those living in major cities (adjusted
OR 0.89; 95% CI 0.83, 0.96). However, individuals living
in very remote areas had 40% increased odds of ceasing
statin use compared with those living in major cities.
Individuals with no previous IHD or CARP history had
increased odds of ceasing compared with those with a
prior history of IHD or CARP (for IHD: adjusted OR 1.17;
95% CI 1.04, 1.31; for CARP: adjusted OR 1.39; 95% CI
1.17, 1.65). New statin users had three times the odds
of cessation compared with individuals with previous
statin usage. General beneficiaries had 41% increased
odds of ceasing statin use compared with concessional
beneficiaries. Those not taking other cardiovascular
medication in 2004 were more likely to cease statin use
(adjusted OR 1.29; 95% CI 1.22, 1.37). A 4% increase
in the odds of ceasing was seen for every additional
medication dispensed. Higher statin adherence levels
in 2004 were significantly associated with individuals
being less likely to cease (adjusted OR 0.98; 95% CI
0.98, 0.98). Sex, socio-economic disadvantage, history of
stroke and taking diabetic medication were not significant
predictors of cessation.
When stratified by beneficiary status, the general
beneficiaries’ age was no longer a significant predictor,
while it was for concessional beneficiary status. For
concessional beneficiaries, residing in a very remote area
was a significant predictor for cessation, while general
beneficiaries living in an inner regional area were less
likely to cease compared to those living in major cities
(Supplementary Table 1A, available from: researchonline.
nd.edu.au/med_article/1022/).

Comparison with 2004
Using 2004–2005 data, 83.9% of statin users continued
their medication in 2005, 12.9% reduced their use by
>20% and 3.2% ceased statin use for at least the first
6 months of 2005. In 2003–2004, 86.0% continued use,
11.6% reduced use and 2.4% ceased use.Therefore,
the likely attributable fraction from the additional PBS
copayment was 0.8% for those who ceased statin
medication, and 1.3% for those who reduced statin
medication.

Characteristics associated with reducing
statin medication in 2005
The overall univariate results (Supplementary
Table 2A, available from: researchonline.nd.edu.au/
med_article/1022/) were similar to the adjusted analysis
(Table 1). When compared with the group that continued
therapy, the odds of reducing statin use were higher
for adults aged <60 years compared with adults aged
>80 years (e.g. 51–60 years adjusted OR 1.13; 95% CI
1.07, 1.20). Greater socio-economic disadvantage was
associated with a reduction; the odds of reducing use
were 13% higher for individuals with the most socioeconomic disadvantage compared to those with the least.
The impact of remoteness varied when compared to
major cities, with individuals living in inner regional areas

Discussion
This study examined individual-level demographic
and clinical characteristics of individuals in WA who
continued, reduced or ceased their statin medication
following the 21% PBS copayment increase in January
2005. We observed that 16% of statin users reduced
or discontinued medication in 2005, and 2.1% of users
appeared to reduce or discontinue medication due to the
copayment increase. Being younger in age and a new
statin user were the two strongest predictors of ceasing
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or reducing statin medication. Greater socio-economic
disadvantage, living in very remote areas, no previous
IHD, no previous CARP, general beneficiary status, not
taking other cardiovascular or diabetic medications,
total medication use, and lower MPR in 2004 were also
associated with either ceasing or reducing use of statin
medication.
Every year, people reduce or cease statin medication,
and previous research has identified many factors that
influence individuals’ decisions to discontinue statin
therapy and adherence levels to therapy. The most
common reason for discontinuation or reduction in statin
therapy is experiencing statin-associated symptoms.18
Other factors include low health literacy, low social status,
existence of comorbid conditions, and polypharmacy.19
An Australian study demonstrated that being older, obese,
having less than excellent self-rated health or prior history
of heart disease resulted in greater statin adherence. Risk
factors for nonadherence included speaking languages
other than English at home, being employed, smoking
and reporting substantial psychological distress.20
The findings from our study support the existing
literature both in Australia and overseas showing
that a copayment increase is associated with more
individuals ceasing or reducing their medication,
and that certain subgroups are more likely to be
affected by a significant increase in the copayment
for medication.1,3,21-24 An Australian study, using selfreporting by 770 participants, found that the groups
most likely to reduce their medication use due to cost
were young adults, low-income earners, the chronically
ill, those with high out-of-pocket costs, Aboriginal and
Torres Strait Islander people, and individuals who did
not feel involved in decisions about their treatment.21
More specifically, the low-income general beneficiaries
group has been classified as the ‘working poor’, who,
despite having a salary, struggle to meet out-of-pocket
medical expenses.25 Previous research on the 2005
January PBS copayment increase using aggregated
data demonstrated that the reduction in use of statin
medication was not specific to remote and disadvantaged
areas, and that the largest impact was seen for lowincome patients.22,26
This study adds to the existing literature by providing
policy makers and clinicians with additional information
about the impacts of large medication copayment
increases on specific subgroups that may be at a higher
risk of being affected.

follow-up (as it includes whole-of-population capture) and
low response as issues for the analysis. This study was
conducted using data from WA, which is representative of
other states and territories in Australia; hence, the study’s
findings are likely to be generalisable to Australia as a
whole.27
This study was restricted to statin medication and did
not analyse whether some individuals may have ceased
or reduced medication because they switched to another
lipid-lowering therapy. However, non-statin lipid-lowering
medication represented only 3% of all lipid-lowering
medications dispensed in 2004.
This study reviewed PBS data between 2002 and
2005, during which time data were not collected on
medications costing less than the patient general
beneficiary copayment or those that were dispensed
privately. This included two of the 14 subsidised statin
medications (fluvastatin 20 mg and simvastatin 5 mg).
The same restrictions would also have affected PBS data
regarding the number of cardiovascular and diabetes
medications, and the number of other medications for
general beneficiaries, by underestimating these variables.
Additionally, PBS data contain no information on dosage;
hence, adherence measures are an estimation based on
an individual’s dispensing history.
Hospital admissions for IHD and stroke may be an
underrepresentation because the look-back period was
from 2000, and hospital admissions outside WA or events
that occurred outside the hospital are not included.
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Conclusion
This study is the first to examine the effects of the January
2005 increase in PBS medication copayments on statin
medication use using individual-level administrative
data. Compared with 2004, an additional 2.1% of statin
users reduced or discontinued medication use in 2005.
Changes in the cessation or reduction in use of statins,
irrespective of the copayment, need attention. Certain
subgroups were more affected, including individuals with
general beneficiary status, and younger and healthier
individuals. These subgroups are not always recognised
as high-risk groups for medication cessation or reduction,
and need to be identified and considered by clinicians
and policy makers.
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